Targeted therapy resistance in EGFR-mutant non-small cell lung cancer: Roles of MET, Trop-2-directed antibody–drug conjugates, and molecular monitoring
Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have substantially improved outcomes in patients with EGFR-mutant non-small cell lung cancer (NSCLC), but acquired resistance remains a major barrier to durable disease control. Objective: This narrative review summarizes the major...